Immunic
IMUX
72 hedge funds and large institutions have $63.4M invested in Immunic in 2022 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 17 increasing their positions, 26 reducing their positions, and 24 closing their positions.
43% more call options, than puts
Call options by funds: $3.66M | Put options by funds: $2.56M
0.36% less ownership
Funds ownership: 6.34% → 5.98% (-0.36%)
11% less funds holding
Funds holding: 81 → 72 (-9)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
33% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 24
35% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 26
68% less capital invested
Capital invested by funds: $200M → $63.4M (-$137M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$7.08M |
| 2 |
Millennium Management
New York
|
+$3.94M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$3.85M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$3.84M |
| 5 |
Janus Henderson Group
London,
|
+$3.27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$6.59M |
| 2 |
BlackRock
New York
|
-$5.4M |
| 3 |
PVI
Pura Vida Investments
New York
|
-$4.38M |
| 4 |
ACM
Altium Capital Management
New York
|
-$3.39M |
| 5 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$2.81M |
IMUX Hedge Fund Activity: Q2 2022 in Review
72 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Immunic (IMUX) for Q2 2022, worth a combined $63.4M — down 68% from $200M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of IMUX and 16 opened new positions — a net loss of 8 holders — while 26 trimmed existing stakes and 17 added.
The largest buyer was Lynx1 Capital Management, opening a new position worth an estimated $7.08M. The largest seller was Sphera Funds Management, exiting entirely with an estimated $6.59M sold.
- 72 institutional investors held Immunic (IMUX) as of Q2 2022, down from 81 in Q1 2022.
- Funds reported $63.4M of Immunic stock for Q2 2022, down 68% quarter-over-quarter.
- 16 funds opened new Immunic positions in Q2 2022 and 24 closed out, a net change of -8 holders.
- The largest Immunic buyer in Q2 2022 was Lynx1 Capital Management, an estimated $7.08M added.
- The largest Immunic seller in Q2 2022 was Sphera Funds Management, an estimated $6.59M sold.
Based on aggregated 13F filings for Q2 2022.